Organoids Lead a New Era in Drug Discovery
Exhibitor: ACROBIOSYSTEMS CO., LTD.
Date: 2025-05-08
Booth No.: M929
Organoids Lead a New Era in Drug Discovery
Genelabs as the Key Distributor in Taiwan, Supporting the Acceleration of Precision Medicine
As biomedical technologies continue to advance, organoids—three-dimensional cell culture systems that replicate the architecture and function of human organs—have become an indispensable tool in disease modeling and drug development. ACROBiosystems' innovative ready-to-use organoid platform offers researchers rapid, reproducible, and scalable solutions, removing traditional barriers to efficient experimentation.
Ready-to-Use Organoids: Faster, Smarter, More Reliable
Conventional organoid systems typically require weeks of stem cell differentiation and sophisticated handling, often resulting in batch-to-batch variability. In contrast, ACROBiosystems’ ready-to-use organoids—covering the brain, heart, liver, and intestine—are pre-differentiated, quality-controlled, and immediately functional, allowing researchers to initiate downstream experiments without delay.
-
Brain organoids simulate neurodegenerative conditions like Alzheimer’s and Parkinson’s diseases and are suitable for neurotoxicity and therapeutic development.
-
Heart organoids exhibit spontaneous beating and electrophysiological features, ideal for cardiotoxicity screening and cardiovascular drug testing.
-
Liver organoids replicate hepatic metabolic and detox functions, supporting accurate prediction of drug-induced liver injury (DILI).
-
Intestinal organoids mimic digestive tract structure and barrier function, useful in modeling gut disorders, microbial interactions, and drug absorption kinetics.
These off-the-shelf organoids eliminate the need for lengthy and complex culturing protocols, saving valuable time, labor, and cost while ensuring consistency and high reproducibility across experiments.
Building Confidence in the Future of Drug Development
According to insights from ACROBiosystems, organoid technology is set to play a pivotal role in next-generation drug discovery. Compared to traditional 2D cell models and animal studies, organoids provide superior physiological relevance, enhancing the predictive power of drug efficacy and toxicity. The recent U.S. FDA decision to allow non-animal data in drug evaluations underscores the growing regulatory acceptance of human-relevant in vitro models.
Driven by the rising demand for personalized medicine, organoids offer a high-fidelity platform for assessing patient-specific responses, improving preclinical success rates and speeding up the translation from bench to bedside. With their robust performance and compatibility with high-throughput screening systems, ready-to-use organoids are poised to become essential tools in precision drug development.
Contact Information
-
For inquiries in Taiwan, please contact Genelabs
Website: https://www.genelabs.com.tw
Phone: +886-2-1234-5678
Email: info@genetika.com.tw -
For international inquiries, please contact your local distributor or ACROBiosystems directly
Website: https://www.acrobiosystems.com
To request technical information or trial samples, feel free to get in touch.
Empower your research with ready-to-use organoids and stay ahead in the race for innovation.
More Exhibitor's Press Release
- GoldenBiotech Seminar:Advancing First-Line Therapy for Metastatic Pancreatic Cancer: Global Phase 3 GOLDEN BIOTECHNOLOGY CORP. / 2025-07-17
- GlobalBio: 國鼎生技-開發Antroquinonol 造福抗癌研究治療 GOLDEN BIOTECHNOLOGY CORP. / 2025-07-17
- Focusing on dementia and brain health APRINOIA THERAPEUTICS INC. / 2025-07-16
- Conquering the Final Hurdle of Cell Therapy Commercialization: Sony Senior Manager to Share Exclusiv CELL-BIO BIOTECHNOLOGY CO., LTD. / 2025-07-16
- Indiana - America's Life Sciences Powerhouse INDIANA ECONOMIC DEVELOPMENT CORPORATION, TAIWAN OFFICE / 2025-07-16
- Urine-Based Cancer Testing: Vitae Biomedical Pioneers a Non-Invasive Path to Lung Cancer Detection VITAE BIOMEDICAL CO. LTD. / 2025-07-16
- IOT無線連續監測系統 - 廠房、倉儲、實驗室 溫、濕度測繪 XIN TOP CORPORATION / 2025-07-15
- MabPlex : ONE-STOP CDMO FOR BIOPHARMACEUTICALS MABPLEX INTERNATIONAL CO., LTD. / 2025-07-15
- Next Generations Therapy Manufacturing LEVITRONIX GMBH TAIWAN BRANCH / 2025-07-15
- The Fastest and Safest Depth Filtration LEVITRONIX GMBH TAIWAN BRANCH / 2025-07-15
- Highest Cell Viability in Perfusion LEVITRONIX GMBH TAIWAN BRANCH / 2025-07-15
- Accelerate Your Exosome Development Timeline: Cell Bio to Unveil Key Analytical Technologies CELL-BIO BIOTECHNOLOGY CO., LTD. / 2025-07-14
- LiZhong Pathology Laboratory Achieves ISO/IEC 17025 Accreditation, Reaching International Standards BIOTNA, INC. / 2025-07-14
- VP-Motion is Japan’s leading AI-powered human behavior analysis software JYTC CO., LTD. / 2025-07-13
- Igus and JYTC walk together for better options. (German beer limited served daily) JYTC CO., LTD. / 2025-07-13
- Why choose Mecademic for robotic lab automation? JYTC CO., LTD. / 2025-07-13
- National Yang Ming Chiao Tung University’s Innovative Biotech and Medical Technologies NATIONAL YANG MING CHIAO TUNG UNIVERSITY / 2025-07-11
- Your Invitation to Innovation – Booth M412 Forum MAJOR SCIENCE CO.,LTD / 2025-07-09
- Cell Bio Biotechnology to Host Three International Authorities at BioAsia 2025, Unveiling a New Era CELL-BIO BIOTECHNOLOGY CO., LTD. / 2025-07-09
- Rooted in Mountains, Climbing the Peaks. BIOMEDICAL TRANSLATION RESEARCH CENTER, ACADEMIA SINICA (NATIONAL BIOTECHNOLOGY RESEARCH PARK) / 2025-07-09